News

Fondazione Penta is pleased to be part of a new international clinical development programme led by Enanta Pharmaceuticals, a clinical-stage biotechnology company, to advance zelicapavir, a new oral antiviral in…

About the author My name is José Sumbana, a young African investigator and Postdoctoral Fellow with a background in Microbiology, Biotechnology, and Life Sciences.

Every winter, hospitals around the world fill with infants struggling to breathe because of respiratory syncytial virus (RSV). Estimates show that RSV infects nearly every child by the time they…

We are pleased to share that Penta’s 2025 Annual Report is now available on our website. For more than thirty years, Penta has worked to ensure that pregnant people,

Looking ahead, Penta is expanding its research horizon by strengthening the integration between basic science, translational research and clinical trials. Over recent years, the Foundation has worked with partners to…

Neonatal sepsis remains a leading cause of newborn mortality across Africa, requiring not only effective antibiotic treatments but also research that is grounded in the needs and realities of families.

In 2025, Penta reached a key milestone by strengthening frontline capacity in paediatric HIV care through the THRIVE Advanced HIV Disease training in Mozambique. Delivered in Maputo in September,

This article was written by Michael Davis Tira, Computer Security Incident Response Team (CSIRT) Representative, Data & Infrastructure Team Manager, and Silvia Cavallo,

Historically, pregnant individuals and infants have been routinely excluded from clinical research under the guise of protection. The PIPELINE project serves as a critical response to this systemic gap, reframing…

In 2025, Penta concluded the VERDI project, a major European collaboration launched to understand the impact of SARS‑CoV‑2 variants and mpox on children and pregnant people. Beyond its scientific outputs,

In 2025, Penta reached a major milestone with the completion of the EPPICC paediatric study on dolutegravir (DTG), a key antiretroviral medicine used in the treatment of children and adolescents…

This article was written by Penta Young Reporter, Arlene. Find out more about the Penta Young Reporters here. What is CHIVA?

This article was originally published in the UCL Innovative Clinical Trials Unit website. Penta contributed to BREATHER+ by coordinating youth involvement through its Youth Trial Boards.

When we think of Tuberculosis (TB), we often picture an adult with a persistent cough. But there is another side that is often left in the shadows, the children who…

Involving young people in clinical research might feel like a leap into the unknown for many researchers, but Penta’s experience shows that it is one of the most rewarding ways…

Women in STEM : the future catalysts for change STEM is ever changing. It is vast, innovative, and transformative. It pioneers the very way in which people live,

Written by Anna Maria Azzini, Stefania Vitali, Evelina Tacconelli, Catherine Fleming, Domenico Benvenuto and Federica Scanavini The historical tragedies linked to the use of medications during pregnancy that caused harm…

For the approximately 2.4 million children and adolescents living with HIV today, managing health is a lifelong commitment that has traditionally relied on a daily three-drug regimen. While adults have…